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Inter-laboratory variability of the standardized ETP-based APC 
resistance assay (PB0386)
INTRODUCTION
• Risk minimiza)on measures need to be implemented to reduce the
thrombo)c risk associated with the use of combined oral
contracep)ves (COC). However, there is controversy on how to
assess the risk at an acceptable cost for the society.
• Despite regulatory bodies recommend the assessment of the ETP-
based ac)vated protein C (APC) resistance during the development
of steroid contracep)ves; results are not comparable between
studies due to lack of valida)on and standardiza)on.
• To overcome this issue, our group recently validated and
standardized this assay.
• However, further inves)ga)ons are needed before a wide
implementa)on of this method.
CONCLUSIONS
• These results demonstrate the transferability of the 
validated ETP-based APC resistance test between 
CATs using the same software version.
• In order to confirm the reliability of the results 
obtained with this validated method, its 
implementation in other centre is essential. 
• The conduct of a larger multi-centre study should 
therefore be performed before implementing this 
technique in the routine setting. 
RESULTS
METHOD
• Analyses were performed on 3 Calibrated Automated
Thrombogram (CAT) with Thrombinoscope soLware (version 5.0 for
CAT1&2; version 2.0 for CAT3) and by 3 different operators.
• Dose-response curves (n=3) were performed on each device to 
defined the amount of APC, leading to 
o (a) 90% of inhibi)on of the ETP on an in-house reference plasma, 
o (b) the corresponding inhibi)on % on a commercial reference 
plasma.
• Quality controls (n=3) and a subset of real-life samples (n=11) were 
tested on each equipment. 
• All measurements were performed in duplicate. 
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AIM
To assess the inter-laboratory variability of the validated ETP-based 
APC resistance assay.
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Defined concentration of APC (95%CI): 217 mU/mL [197 mU/mL-249 mU/mL]
Inhibition % 
Difference 
CAT 1 CAT 2
In-house ref




QC Low 98,19% 100,16% 1,96%
QC Norm 31,22% 44,17% 12,95%
QC High 7,18% 9,70% 2,52%
S1 91,99% 96,34% 4,36%
S2 77,01% 81,54% 4,53%
S3 78,53% 86,07% 7,54%
S4 64,74% 74,16% 9,42%
S5 56,94% 64,92% 7,97%
S6 68,84% 79,33% 10,49%
S7 69,03% 76,53% 7,49%
S8 69,02% 76,42% 7,40%
S9 46,88% 60,55% 13,67%
S10 61,99% 71,36% 9,37%
S11 40,69% 50,90% 10,21%
Mean deviation 7,83%
• A mean devia)on of 7.83% was
observed when comparing samples
tested on both CAT device at the
defined APC concentra)on of 217
mU/mL (▶Table 2).
• Dose-response curves did not show any significant differences between CAT1 and CAT2 (Dunn’s 
mul)ple comparison test; p-value > 0.9999) on both, commercial and in-house reference plasma                            
▶Table/Figure 1. 
• An APC concentra)on of 217 mU/mL led to 90% of inhibi)on of the ETP on the homemade
reference plasma and 68% of inhibi)on on the commercial reference plasma
▶Table/Figure 1.


















TABLE 2: Inhibi'on percentage
and absolute difference
between CAT1 and CAT2.
FIGURE 1: Total variability between CAT1 and CAT2. The red do>ed line represents the
reference range of in-house reference plasma (90±2.5%) and the blue do>ed line represents
the reference range of commercial reference plasma (68±8%). The green do>ed line
represents the defined concentra'on of APC (217 mU/mL) to fit the reference ranges.
TABLE 1: Inhibi'on percentage at 6 concentra'on levels of APC with in-house reference
plasma and commercial reference plasma on CAT1 and CAT2. Inhibi'on % in blue* are
outliers
• As the software










older version of the
CAT3 at low ETP-values.
